enGene

At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid),...

Gene therapy,urology,oncology,immunotherapy,nmibc,non-muscle invasive bladder cancer,bladder cancer,dna,rna,genetic medicines,mucosal tissues,non-viral gene therapy,eg-70,cytokine il-12,interleukin-12,and drug development

Engene operates in the Biotechnology research industry.

Engene's revenue is 11m - 100m

Engene has 51 - 200 employees.